Salubris Biotherapeutics

Salubris Biotherapeutics is a clinical-stage biotechnology company focused on developing complex biologic therapeutics for cardiovascular, oncology, and neurodegenerative diseases. They have a robust pipeline of first-in-class treatments, including JK07, an antibody fusion protein for heart failure, JK08, an IL15-CTLA4 antibody fusion for solid tumors, and JK06, a biparatopic antibody-drug conjugate targeting 5T4 for cancer. Their research is driven by a commitment to innovation and the development of therapies for large patient populations with significant unmet medical needs.

SalubrisBio was founded in 2016 as a wholly-owned subsidiary of Shenzhen Salubris Pharmaceuticals Co. Ltd. Headquartered in the US, they reflect their parent company's dedication to innovation and global expansion. They are committed to advancing their research and development programs through clinical trials, with a focus on developing safe and effective treatments that improve patient outcomes.

Salubris Biotherapeutics is a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics for cardiovascular, oncology, and neurodegenerative diseases. Their mission is to develop first-in-class biologics that improve the health and quality of life for people living with complicated diseases. They focus on creating innovative and transformative therapeutic molecules that address significant unmet medical needs, striving to deliver novel biologic therapies to patients.

Salubris Biotherapeutics promotes a culture of innovation, collaboration, and dedication to improving patient lives. The company's website highlights its team of biotech industry experts who are passionate about discovering and developing novel therapies. They emphasize teamwork and problem-solving, creating a dynamic environment where individuals can contribute their expertise and work together towards shared goals. This culture is driven by a commitment to excellence in the field of complex biologics and a desire to make a meaningful difference in the lives of patients.

Salubris Biotherapeutics does not explicitly state its approach to diversity, equity, and inclusion on their website. However, they do mention their commitment to building a team of biotech industry experts brought together by a shared passion and commitment to excellence in the discovery and development of novel therapies. This suggests a focus on attracting and retaining a talented workforce, regardless of background.